Synlogic, Inc. Common Stock, also called Synlogic, is a clinical-stage biopharmaceutical company. Read More It engages in drug discovery and development of synthetic biotic medicines. The firm focuses on SYNB1020 and SYNB1618, which are orally administered and target hyperammonemia and phenylketonuria. It also works on SYNB1891, an intratumorally administered which treats cancer. The company was founded by Jim Collins and Tim Lu on August 28, 2017, and is headquartered in Cambridge, MA. The listed name for SYBX is Synlogic, Inc. Common Stock.